TSBX Turnstone Biologics Corp. Common Stock
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 8
- List Date
- 2023-07-21
- CIK
- 0001764974
- Headquarters
- La Jolla, CA
- Homepage
- https://www.turnstonebio.com
Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes…
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
Click Frenzy-Pro™ for an AI analysis of this ticker.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
TSBX Options Activity & IV Rank
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Enter a ticker to render the implied volatility surface.
Enter a ticker to render the implied volatility smile.
TSBX Institutional Ownership (13F)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
TSBX Insider Trading (Form 4)
Latest: 2025-08-12| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2025-08-12 | OrbiMed Capital GP VI LLC | Director | U | −6,198,530 | — | EDGAR | |
| 2025-08-12 | Versant Ventures V, LLC | 10%+ Owner | U | −33,816,920 | — | EDGAR | |
| 2025-08-08 | Rishi Gupta | Director | U | −3,099,265 | — | EDGAR | |
| 2025-08-08 | Davis Jerel | Director | U | −3,381,692 | — | EDGAR | |
| 2024-07-02 | Kanya Rajangam | Director | Grant (A) | +12,770 opt | — | EDGAR | |
| 2024-07-02 | William D. Waddill | Director | Grant (A) | +12,770 opt | — | EDGAR | |
| 2024-07-02 | Robert J Gould | Director | Grant (A) | +12,770 opt | — | EDGAR | |
| 2024-07-02 | Davis Jerel | Director | Grant (A) | +12,770 opt | — | EDGAR | |
| 2024-07-02 | Rishi Gupta | Director | Grant (A) | +12,770 opt | — | EDGAR | |
| 2024-04-16 | William D. Waddill | Director | Grant (A) | +25,540 opt | — | EDGAR | |
| 2024-01-11 | FMR LLC | — | — | — | EDGAR | ||
| 2023-10-17 | Venkat Ramanan | Chief Financial Officer | Grant (A) | +46,606 opt | — | EDGAR | |
| 2023-10-17 | Rishi Gupta | Director | Grant (A) | +25,540 opt | — | EDGAR | |
| 2023-10-17 | Peter Joseph Campisi Jr. | Chief Legal Officer | Grant (A) | +44,377 opt | — | EDGAR | |
| 2023-10-17 | Stewart Abbot | Chief Scientific Officer | Grant (A) | +45,542 opt | — | EDGAR |
TSBX Board & Officers
As of SEC filings through Aug 12, 2025Directors 5
- Davis Jerel · since Jul 20, 2023
- Michael F. Burgess · since Jul 20, 2023
- OrbiMed Capital GP VI LLC (entity) · since Jul 20, 2023
- Orbimed Advisors LLC (entity) · since Jul 20, 2023
- Sammy J. Farah · since Jul 20, 2023
Officers 6
- Sammy J. Farah · President & CEO · since Jul 20, 2023
- Michael F. Burgess · Interim Chief Medical Officer · since Jul 20, 2023
- Peter Joseph Campisi Jr. · Chief Legal Officer · since Jul 20, 2023
- Saryah Azmat · Chief Business Officer · since Jul 20, 2023
- Stewart Abbot · Chief Scientific Officer · since Jul 20, 2023
- Vijay Chiruvolu · Int. Chief Technology Officer · since Jul 20, 2023
10% owners 4
- Davis Jerel · since Jul 20, 2023
- OrbiMed Capital GP VI LLC (entity) · since Jul 20, 2023
- Orbimed Advisors LLC (entity) · since Jul 20, 2023
- Rishi Gupta · since Jul 20, 2023
Changes in the last 10 years (49)
| Aug 12, 2025 | Versant Ventures V, LLC reported in an SEC filing no longer being a 10% owner |
| Aug 12, 2025 | Versant Ventures V GP-GP (Canada), Inc. reported in an SEC filing no longer being a 10% owner |
| Aug 12, 2025 | Versant Ventures V (Canada), L.P. reported in an SEC filing no longer being a 10% owner |
| Aug 12, 2025 | Versant Venture Capital V, L.P. reported in an SEC filing no longer being a 10% owner |
| Aug 12, 2025 | Versant Venture Capital V (Canada), LP reported in an SEC filing no longer being a 10% owner |
| Aug 12, 2025 | Versant Vantage II, L.P. reported in an SEC filing no longer being a 10% owner |
| Aug 12, 2025 | Versant Vantage II GP-GP, LLC reported in an SEC filing no longer being a 10% owner |
| Aug 12, 2025 | Versant Vantage II GP, L.P. reported in an SEC filing no longer being a 10% owner |
| Aug 12, 2025 | Versant Ophthalmic Affiliates I, L.P. reported in an SEC filing no longer being a 10% owner |
| Aug 12, 2025 | Versant Affiliates Fund V, L.P. reported in an SEC filing no longer being a 10% owner |
| Aug 11, 2025 | The company announced the departure of William D. Waddill from the board in an SEC filing |
| Aug 11, 2025 | The company announced the departure of Robert J Gould from the board in an SEC filing |
| Aug 11, 2025 | The company announced the departure of Rishi Gupta from the board in an SEC filing |
| Aug 11, 2025 | The company announced the departure of Kanya Rajangam from the board in an SEC filing |
| Oct 9, 2024 | The company announced the departure of Venkat Ramanan as Chief Financial Officer in an SEC filing |
| Apr 15, 2024 | William D. Waddill became a director |
| Apr 12, 2024 | The company announced the departure of Patrick Machado from the board in an SEC filing |
| Jan 11, 2024 | Fmr LLC reported in an SEC filing no longer being a 10% owner |
| Jul 20, 2023 | Vijay Chiruvolu became Int. Chief Technology Officer |
| Jul 20, 2023 | Versant Ventures V, LLC became a 10% owner |
| Jul 20, 2023 | Versant Ventures V GP-GP (Canada), Inc. became a 10% owner |
| Jul 20, 2023 | Versant Ventures V (Canada), L.P. became a 10% owner |
| Jul 20, 2023 | Versant Venture Capital V, L.P. became a 10% owner |
| Jul 20, 2023 | Versant Venture Capital V (Canada), LP became a 10% owner |
| Jul 20, 2023 | Versant Vantage II, L.P. became a 10% owner |
| Jul 20, 2023 | Versant Vantage II GP-GP, LLC became a 10% owner |
| Jul 20, 2023 | Versant Vantage II GP, L.P. became a 10% owner |
| Jul 20, 2023 | Versant Ophthalmic Affiliates I, L.P. became a 10% owner |
| Jul 20, 2023 | Versant Affiliates Fund V, L.P. became a 10% owner |
| Jul 20, 2023 | Venkat Ramanan became Chief Financial Officer |
| Jul 20, 2023 | Stewart Abbot became Chief Scientific Officer |
| Jul 20, 2023 | Saryah Azmat became Chief Business Officer |
| Jul 20, 2023 | Sammy J. Farah became a director |
| Jul 20, 2023 | Sammy J. Farah became President & CEO |
| Jul 20, 2023 | Robert J Gould became a director |
| Jul 20, 2023 | Rishi Gupta became a director |
| Jul 20, 2023 | Rishi Gupta became a 10% owner |
| Jul 20, 2023 | Peter Joseph Campisi Jr. became Chief Legal Officer |
| Jul 20, 2023 | Patrick Machado became a director |
| Jul 20, 2023 | Orbimed Advisors LLC became a director |
| Jul 20, 2023 | Orbimed Advisors LLC became a 10% owner |
| Jul 20, 2023 | OrbiMed Capital GP VI LLC became a director |
| Jul 20, 2023 | OrbiMed Capital GP VI LLC became a 10% owner |
| Jul 20, 2023 | Michael F. Burgess became a director |
| Jul 20, 2023 | Michael F. Burgess became Interim Chief Medical Officer |
| Jul 20, 2023 | Kanya Rajangam became a director |
| Jul 20, 2023 | Fmr LLC became a 10% owner |
| Jul 20, 2023 | Davis Jerel became a director |
| Jul 20, 2023 | Davis Jerel became a 10% owner |
- Prev
- 1
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.